We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEHC icon
26
GE HealthCare
GEHC
$28.7B
$42.3M 0.95%
524,414
– –
CI icon
27
Cigna
CI
$74.5B
$38.7M 0.87%
117,535
-7,670
-6% -$2.31M
RMD icon
28
ResMed
RMD
$28.9B
$37.1M 0.83%
165,802
+5,009
+3% +$1.17M
IMCR icon
29
Immunocore
IMCR
$1.78B
$36.3M 0.81%
1,221,794
+16,330
+1% +$490K
LLY icon
30
Eli Lilly
LLY
$1.05T
$36M 0.81%
43,647
-1,818
-4% -$1.51M
WVE icon
31
Wave Life Sciences
WVE
$1.12B
$33.1M 0.74%
4,094,458
– –
ZBH icon
32
Zimmer Biomet
ZBH
$17.6B
$33M 0.74%
291,346
-2,275
-0.8% -$243K
IDXX icon
33
Idexx Laboratories
IDXX
$44.8B
$32.3M 0.72%
76,897
-38
-0% -$16.5K
TMO icon
34
Thermo Fisher Scientific
TMO
$198B
$32M 0.72%
64,232
+3,270
+5% +$1.77M
EWTX icon
35
Edgewise Therapeutics
EWTX
$4.28B
$31.4M 0.7%
1,428,929
– –
COO icon
36
Cooper Companies
COO
$14B
$30.1M 0.67%
357,025
-105
-0% -$9.41K
ABBV icon
37
AbbVie
ABBV
$450B
$28.3M 0.63%
135,240
+89,981
+199% +$17.5M
VEEV icon
38
Veeva Systems
VEEV
$31.7B
$26.2M 0.59%
113,250
-14,325
-11% -$3.27M
BMRN icon
39
BioMarin Pharmaceuticals
BMRN
$11.5B
$26M 0.58%
368,373
+39,352
+12% +$2.65M
DHR icon
40
Danaher
DHR
$144B
$25.5M 0.57%
124,321
+4,399
+4% +$960K
AMGN icon
41
Amgen
AMGN
$198B
$25.2M 0.57%
80,935
-8,305
-9% -$2.45M
EXAS
42
DELISTED
Exact Sciences
EXAS
$25.1M 0.56%
579,074
-114,982
-17% -$5.82M
MOH icon
43
Molina Healthcare
MOH
$11.7B
$25M 0.56%
75,895
-6,256
-8% -$1.89M
STE icon
44
Steris
STE
$21.2B
$24.9M 0.56%
109,887
– –
GMED icon
45
Globus Medical
GMED
$10.5B
$24.3M 0.55%
332,336
-30,643
-8% -$2.53M
PRCT icon
46
Procept Biorobotics
PRCT
$1.09B
$24.2M 0.54%
414,923
-47,971
-10% -$3.28M
ALGN icon
47
Align Technology
ALGN
$12.7B
$24M 0.54%
150,993
-9,010
-6% -$1.77M
HCA icon
48
HCA Healthcare
HCA
$82.3B
$21.4M 0.48%
61,807
-76
-0.1% -$24.4K
MRK icon
49
Merck
MRK
$315B
$20.8M 0.47%
231,371
-32,855
-12% -$3.07M
MCK icon
50
McKesson
MCK
$98.5B
$20.6M 0.46%
30,580
+11,265
+58% +$6.96M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.